Acropolis Investment Management LLC boosted its stake in Pfizer Inc. (NYSE:PFE) by 6.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 12,151 shares of the biopharmaceutical company’s stock after purchasing an additional 736 shares during the period. Acropolis Investment Management LLC’s holdings in Pfizer were worth $447,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in PFE. United Bank grew its holdings in shares of Pfizer by 7.5% in the 2nd quarter. United Bank now owns 53,712 shares of the biopharmaceutical company’s stock worth $1,756,000 after acquiring an additional 3,766 shares during the period. Principal Financial Group Inc. raised its holdings in shares of Pfizer by 4.6% during the 2nd quarter. Principal Financial Group Inc. now owns 13,412,027 shares of the biopharmaceutical company’s stock valued at $438,573,000 after buying an additional 587,393 shares during the period. Engineers Gate Manager LP boosted its stake in shares of Pfizer by 47.4% in the second quarter. Engineers Gate Manager LP now owns 52,802 shares of the biopharmaceutical company’s stock valued at $1,727,000 after purchasing an additional 16,981 shares during the period. RMR Wealth Builders purchased a new stake in Pfizer during the 2nd quarter worth $91,000. Finally, WFA of San Diego LLC purchased a new position in Pfizer in the 2nd quarter valued at about $269,000. Institutional investors own 69.08% of the company’s stock.
In other news, major shareholder Pfizer Inc purchased 1,200,000 shares of the company’s stock in a transaction dated Tuesday, October 27th. The shares were bought at an average price of $10.00 per share, with a total value of $12,000,000.00. Following the completion of the transaction, the insider now directly owns 27,349,211 shares in the company, valued at approximately $273,492,110. The purchase was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.08% of the company’s stock.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 27th. The biopharmaceutical company reported $0.72 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.01. The company had revenue of $12.13 billion during the quarter, compared to analysts’ expectations of $12.30 billion. Pfizer had a return on equity of 25.11% and a net margin of 28.80%. The business’s quarterly revenue was down 4.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.75 earnings per share. On average, sell-side analysts forecast that Pfizer Inc. will post 2.84 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, March 5th. Shareholders of record on Friday, January 29th will be given a dividend of $0.39 per share. The ex-dividend date is Thursday, January 28th. This represents a $1.56 dividend on an annualized basis and a yield of 4.23%. This is a boost from Pfizer’s previous quarterly dividend of $0.38. Pfizer’s dividend payout ratio is presently 51.53%.
PFE has been the subject of a number of analyst reports. Sanford C. Bernstein assumed coverage on Pfizer in a report on Tuesday, November 10th. They issued a “market perform” rating and a $42.00 price target for the company. Atlantic Securities cut Pfizer from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $44.00 to $39.00 in a research note on Monday, October 12th. SVB Leerink lifted their target price on Pfizer from $42.00 to $43.00 and gave the stock a “market perform” rating in a research report on Wednesday, October 28th. Berenberg Bank began coverage on Pfizer in a report on Tuesday, September 29th. They issued a “hold” rating and a $38.00 price target for the company. Finally, TheStreet upgraded Pfizer from a “c+” rating to a “b-” rating in a research note on Wednesday, November 25th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have issued a buy rating to the stock. Pfizer has a consensus rating of “Hold” and a consensus target price of $39.87.
Pfizer Inc develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands.
Featured Story: Quick Ratio
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.